http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 17 Jun 2026 07:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Sernova+Biotherapeutics+Receives+FDA+Orphan+Drug+Designation+for+Autologous+Islet+Transplantation+for+Prevention+of+Diabetes+Due+to+Total+Pancreatectomy/26656688.html <p align="justify">TORONTO and BOSTON, June 17, 2026 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics Inc. (“Sernova” or the “Company”) (TSX: SVA) (OTC: SEOVF) (FSE/XETRA: PSHO), a leading regenerative medicine company focused on developing its Cell Pouch Bio-hybrid Organ as a functional cure for type 1 diabetes, today announced that the U.S. Food and Drug Administration (“FDA”) has granted orphan drug designation for autologous islet transplantation (“AIT”) for the prevention of diabetes due to total pancreatectomy.</p> <p align="justify">Sernova’s proprietary Cell Pouch Bio-hybrid Organ is designed to support the engraftment and long-term function of transplanted therapeutic cells. Chronic Pancreatitis causes debilitating http://www.streetinsider.com/Press+Releases/Sernova+Biotherapeutics+Receives+FDA+Orphan+Drug+Designation+for+Autologous+Islet+Transplantation+for+Prevention+of+Diabetes+Due+to+Total+Pancreatectomy/26656688.html Wed, 17 Jun 2026 07:00:00 -0400 A.06822034 A.28110669 O.03140503 O.20026344 O.48401414 PSH PSH.DE SEOVF SVA http://www.streetinsider.com/Press+Releases/Sernova+Biotherapeutics+Receives+FDA+Orphan+Drug+Designation+for+Autologous+Islet+Transplantation+for+Prevention+of+Diabetes+Due+to+Total+Pancreatectomy/26656688.html <p align="justify">TORONTO and BOSTON, June 17, 2026 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics Inc. (“Sernova” or the “Company”) (TSX: SVA) (OTC: SEOVF) (FSE/XETRA: PSHO), a leading regenerative medicine company focused on developing its Cell Pouch Bio-hybrid Organ as a functional cure for type 1 diabetes, today announced that the U.S. Food and Drug Administration (“FDA”) has granted orphan drug designation for autologous islet transplantation (“AIT”) for the prevention of diabetes due to total pancreatectomy.</p> <p align="justify">Sernova’s proprietary Cell Pouch Bio-hybrid Organ is designed to support the engraftment and long-term function of transplanted therapeutic cells. Chronic Pancreatitis causes debilitating http://www.streetinsider.com/Press+Releases/Sernova+Biotherapeutics+Receives+FDA+Orphan+Drug+Designation+for+Autologous+Islet+Transplantation+for+Prevention+of+Diabetes+Due+to+Total+Pancreatectomy/26656688.html Wed, 17 Jun 2026 07:00:00 -0400 A.06822034 A.28110669 O.03140503 O.20026344 O.48401414 PSH PSH.DE SEOVF SVA http://www.streetinsider.com/Press+Releases/Sernova+Biotherapeutics+Receives+FDA+Orphan+Drug+Designation+for+Autologous+Islet+Transplantation+for+Prevention+of+Diabetes+Due+to+Total+Pancreatectomy/26656688.html <p align="justify">TORONTO and BOSTON, June 17, 2026 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics Inc. (“Sernova” or the “Company”) (TSX: SVA) (OTC: SEOVF) (FSE/XETRA: PSHO), a leading regenerative medicine company focused on developing its Cell Pouch Bio-hybrid Organ as a functional cure for type 1 diabetes, today announced that the U.S. Food and Drug Administration (“FDA”) has granted orphan drug designation for autologous islet transplantation (“AIT”) for the prevention of diabetes due to total pancreatectomy.</p> <p align="justify">Sernova’s proprietary Cell Pouch Bio-hybrid Organ is designed to support the engraftment and long-term function of transplanted therapeutic cells. Chronic Pancreatitis causes debilitating http://www.streetinsider.com/Press+Releases/Sernova+Biotherapeutics+Receives+FDA+Orphan+Drug+Designation+for+Autologous+Islet+Transplantation+for+Prevention+of+Diabetes+Due+to+Total+Pancreatectomy/26656688.html Wed, 17 Jun 2026 07:00:00 -0400 A.06822034 A.28110669 O.03140503 O.20026344 O.48401414 PSH PSH.DE SEOVF SVA http://www.streetinsider.com/Press+Releases/Sernova+Biotherapeutics+Receives+FDA+Orphan+Drug+Designation+for+Autologous+Islet+Transplantation+for+Prevention+of+Diabetes+Due+to+Total+Pancreatectomy/26656688.html <p align="justify">TORONTO and BOSTON, June 17, 2026 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics Inc. (“Sernova” or the “Company”) (TSX: SVA) (OTC: SEOVF) (FSE/XETRA: PSHO), a leading regenerative medicine company focused on developing its Cell Pouch Bio-hybrid Organ as a functional cure for type 1 diabetes, today announced that the U.S. Food and Drug Administration (“FDA”) has granted orphan drug designation for autologous islet transplantation (“AIT”) for the prevention of diabetes due to total pancreatectomy.</p> <p align="justify">Sernova’s proprietary Cell Pouch Bio-hybrid Organ is designed to support the engraftment and long-term function of transplanted therapeutic cells. Chronic Pancreatitis causes debilitating http://www.streetinsider.com/Press+Releases/Sernova+Biotherapeutics+Receives+FDA+Orphan+Drug+Designation+for+Autologous+Islet+Transplantation+for+Prevention+of+Diabetes+Due+to+Total+Pancreatectomy/26656688.html Wed, 17 Jun 2026 07:00:00 -0400 A.06822034 A.28110669 O.03140503 O.20026344 O.48401414 PSH PSH.DE SEOVF SVA http://www.streetinsider.com/Press+Releases/Sernova+Biotherapeutics+Receives+FDA+Orphan+Drug+Designation+for+Autologous+Islet+Transplantation+for+Prevention+of+Diabetes+Due+to+Total+Pancreatectomy/26656688.html <p align="justify">TORONTO and BOSTON, June 17, 2026 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics Inc. (“Sernova” or the “Company”) (TSX: SVA) (OTC: SEOVF) (FSE/XETRA: PSHO), a leading regenerative medicine company focused on developing its Cell Pouch Bio-hybrid Organ as a functional cure for type 1 diabetes, today announced that the U.S. Food and Drug Administration (“FDA”) has granted orphan drug designation for autologous islet transplantation (“AIT”) for the prevention of diabetes due to total pancreatectomy.</p> <p align="justify">Sernova’s proprietary Cell Pouch Bio-hybrid Organ is designed to support the engraftment and long-term function of transplanted therapeutic cells. Chronic Pancreatitis causes debilitating http://www.streetinsider.com/Press+Releases/Sernova+Biotherapeutics+Receives+FDA+Orphan+Drug+Designation+for+Autologous+Islet+Transplantation+for+Prevention+of+Diabetes+Due+to+Total+Pancreatectomy/26656688.html Wed, 17 Jun 2026 07:00:00 -0400 A.06822034 A.28110669 O.03140503 O.20026344 O.48401414 PSH PSH.DE SEOVF SVA http://www.streetinsider.com/Press+Releases/Sernova+Biotherapeutics+Receives+FDA+Orphan+Drug+Designation+for+Autologous+Islet+Transplantation+for+Prevention+of+Diabetes+Due+to+Total+Pancreatectomy/26656688.html <p align="justify">TORONTO and BOSTON, June 17, 2026 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics Inc. (“Sernova” or the “Company”) (TSX: SVA) (OTC: SEOVF) (FSE/XETRA: PSHO), a leading regenerative medicine company focused on developing its Cell Pouch Bio-hybrid Organ as a functional cure for type 1 diabetes, today announced that the U.S. Food and Drug Administration (“FDA”) has granted orphan drug designation for autologous islet transplantation (“AIT”) for the prevention of diabetes due to total pancreatectomy.</p> <p align="justify">Sernova’s proprietary Cell Pouch Bio-hybrid Organ is designed to support the engraftment and long-term function of transplanted therapeutic cells. Chronic Pancreatitis causes debilitating http://www.streetinsider.com/Press+Releases/Sernova+Biotherapeutics+Receives+FDA+Orphan+Drug+Designation+for+Autologous+Islet+Transplantation+for+Prevention+of+Diabetes+Due+to+Total+Pancreatectomy/26656688.html Wed, 17 Jun 2026 07:00:00 -0400 A.06822034 A.28110669 O.03140503 O.20026344 O.48401414 PSH PSH.DE SEOVF SVA http://www.streetinsider.com/Press+Releases/Sernova+Biotherapeutics+Receives+FDA+Orphan+Drug+Designation+for+Autologous+Islet+Transplantation+for+Prevention+of+Diabetes+Due+to+Total+Pancreatectomy/26656688.html <p align="justify">TORONTO and BOSTON, June 17, 2026 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics Inc. (“Sernova” or the “Company”) (TSX: SVA) (OTC: SEOVF) (FSE/XETRA: PSHO), a leading regenerative medicine company focused on developing its Cell Pouch Bio-hybrid Organ as a functional cure for type 1 diabetes, today announced that the U.S. Food and Drug Administration (“FDA”) has granted orphan drug designation for autologous islet transplantation (“AIT”) for the prevention of diabetes due to total pancreatectomy.</p> <p align="justify">Sernova’s proprietary Cell Pouch Bio-hybrid Organ is designed to support the engraftment and long-term function of transplanted therapeutic cells. Chronic Pancreatitis causes debilitating http://www.streetinsider.com/Press+Releases/Sernova+Biotherapeutics+Receives+FDA+Orphan+Drug+Designation+for+Autologous+Islet+Transplantation+for+Prevention+of+Diabetes+Due+to+Total+Pancreatectomy/26656688.html Wed, 17 Jun 2026 07:00:00 -0400 A.06822034 A.28110669 O.03140503 O.20026344 O.48401414 PSH PSH.DE SEOVF SVA http://www.streetinsider.com/Press+Releases/Sernova+Biotherapeutics+Receives+FDA+Orphan+Drug+Designation+for+Autologous+Islet+Transplantation+for+Prevention+of+Diabetes+Due+to+Total+Pancreatectomy/26656688.html <p align="justify">TORONTO and BOSTON, June 17, 2026 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics Inc. (“Sernova” or the “Company”) (TSX: SVA) (OTC: SEOVF) (FSE/XETRA: PSHO), a leading regenerative medicine company focused on developing its Cell Pouch Bio-hybrid Organ as a functional cure for type 1 diabetes, today announced that the U.S. Food and Drug Administration (“FDA”) has granted orphan drug designation for autologous islet transplantation (“AIT”) for the prevention of diabetes due to total pancreatectomy.</p> <p align="justify">Sernova’s proprietary Cell Pouch Bio-hybrid Organ is designed to support the engraftment and long-term function of transplanted therapeutic cells. Chronic Pancreatitis causes debilitating http://www.streetinsider.com/Press+Releases/Sernova+Biotherapeutics+Receives+FDA+Orphan+Drug+Designation+for+Autologous+Islet+Transplantation+for+Prevention+of+Diabetes+Due+to+Total+Pancreatectomy/26656688.html Wed, 17 Jun 2026 07:00:00 -0400 A.06822034 A.28110669 O.03140503 O.20026344 O.48401414 PSH PSH.DE SEOVF SVA http://www.streetinsider.com/Press+Releases/Sernova+Biotherapeutics+Receives+FDA+Orphan+Drug+Designation+for+Autologous+Islet+Transplantation+for+Prevention+of+Diabetes+Due+to+Total+Pancreatectomy/26656688.html <p align="justify">TORONTO and BOSTON, June 17, 2026 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics Inc. (“Sernova” or the “Company”) (TSX: SVA) (OTC: SEOVF) (FSE/XETRA: PSHO), a leading regenerative medicine company focused on developing its Cell Pouch Bio-hybrid Organ as a functional cure for type 1 diabetes, today announced that the U.S. Food and Drug Administration (“FDA”) has granted orphan drug designation for autologous islet transplantation (“AIT”) for the prevention of diabetes due to total pancreatectomy.</p> <p align="justify">Sernova’s proprietary Cell Pouch Bio-hybrid Organ is designed to support the engraftment and long-term function of transplanted therapeutic cells. Chronic Pancreatitis causes debilitating http://www.streetinsider.com/Press+Releases/Sernova+Biotherapeutics+Receives+FDA+Orphan+Drug+Designation+for+Autologous+Islet+Transplantation+for+Prevention+of+Diabetes+Due+to+Total+Pancreatectomy/26656688.html Wed, 17 Jun 2026 07:00:00 -0400 A.06822034 A.28110669 O.03140503 O.20026344 O.48401414 PSH PSH.DE SEOVF SVA http://www.streetinsider.com/Globe+Newswire/Sernova+Biotherapeutics+Receives+FDA+Orphan+Drug+Designation+for+Autologous+Islet+Transplantation+for+Prevention+of+Diabetes+Due+to+Total+Pancreatectomy/26656688.html <p align="justify">TORONTO and BOSTON, June 17, 2026 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics Inc. (“Sernova” or the “Company”) (TSX: SVA) (OTC: SEOVF) (FSE/XETRA: PSHO), a leading regenerative medicine company focused on developing its Cell Pouch Bio-hybrid Organ as a functional cure for type 1 diabetes, today announced that the U.S. Food and Drug Administration (“FDA”) has granted orphan drug designation for autologous islet transplantation (“AIT”) for the prevention of diabetes due to total pancreatectomy.</p> <p align="justify">Sernova’s proprietary Cell Pouch Bio-hybrid Organ is designed to support the engraftment and long-term function of transplanted therapeutic cells. Chronic Pancreatitis causes debilitating http://www.streetinsider.com/Globe+Newswire/Sernova+Biotherapeutics+Receives+FDA+Orphan+Drug+Designation+for+Autologous+Islet+Transplantation+for+Prevention+of+Diabetes+Due+to+Total+Pancreatectomy/26656688.html Wed, 17 Jun 2026 07:00:00 -0400 A.06822034 A.28110669 O.03140503 O.20026344 O.48401414 PSH PSH.DE SEOVF SVA http://www.streetinsider.com/Globe+Newswire/Sernova+Biotherapeutics+Receives+FDA+Orphan+Drug+Designation+for+Autologous+Islet+Transplantation+for+Prevention+of+Diabetes+Due+to+Total+Pancreatectomy/26656688.html <p align="justify">TORONTO and BOSTON, June 17, 2026 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics Inc. (“Sernova” or the “Company”) (TSX: SVA) (OTC: SEOVF) (FSE/XETRA: PSHO), a leading regenerative medicine company focused on developing its Cell Pouch Bio-hybrid Organ as a functional cure for type 1 diabetes, today announced that the U.S. Food and Drug Administration (“FDA”) has granted orphan drug designation for autologous islet transplantation (“AIT”) for the prevention of diabetes due to total pancreatectomy.</p> <p align="justify">Sernova’s proprietary Cell Pouch Bio-hybrid Organ is designed to support the engraftment and long-term function of transplanted therapeutic cells. Chronic Pancreatitis causes debilitating http://www.streetinsider.com/Globe+Newswire/Sernova+Biotherapeutics+Receives+FDA+Orphan+Drug+Designation+for+Autologous+Islet+Transplantation+for+Prevention+of+Diabetes+Due+to+Total+Pancreatectomy/26656688.html Wed, 17 Jun 2026 07:00:00 -0400 A.06822034 A.28110669 O.03140503 O.20026344 O.48401414 PSH PSH.DE SEOVF SVA http://www.streetinsider.com/Globe+Newswire/Sernova+Biotherapeutics+Receives+FDA+Orphan+Drug+Designation+for+Autologous+Islet+Transplantation+for+Prevention+of+Diabetes+Due+to+Total+Pancreatectomy/26656688.html <p align="justify">TORONTO and BOSTON, June 17, 2026 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics Inc. (“Sernova” or the “Company”) (TSX: SVA) (OTC: SEOVF) (FSE/XETRA: PSHO), a leading regenerative medicine company focused on developing its Cell Pouch Bio-hybrid Organ as a functional cure for type 1 diabetes, today announced that the U.S. Food and Drug Administration (“FDA”) has granted orphan drug designation for autologous islet transplantation (“AIT”) for the prevention of diabetes due to total pancreatectomy.</p> <p align="justify">Sernova’s proprietary Cell Pouch Bio-hybrid Organ is designed to support the engraftment and long-term function of transplanted therapeutic cells. Chronic Pancreatitis causes debilitating http://www.streetinsider.com/Globe+Newswire/Sernova+Biotherapeutics+Receives+FDA+Orphan+Drug+Designation+for+Autologous+Islet+Transplantation+for+Prevention+of+Diabetes+Due+to+Total+Pancreatectomy/26656688.html Wed, 17 Jun 2026 07:00:00 -0400 A.06822034 A.28110669 O.03140503 O.20026344 O.48401414 PSH PSH.DE SEOVF SVA http://www.streetinsider.com/Globe+Newswire/Sernova+Biotherapeutics+Receives+FDA+Orphan+Drug+Designation+for+Autologous+Islet+Transplantation+for+Prevention+of+Diabetes+Due+to+Total+Pancreatectomy/26656688.html <p align="justify">TORONTO and BOSTON, June 17, 2026 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics Inc. (“Sernova” or the “Company”) (TSX: SVA) (OTC: SEOVF) (FSE/XETRA: PSHO), a leading regenerative medicine company focused on developing its Cell Pouch Bio-hybrid Organ as a functional cure for type 1 diabetes, today announced that the U.S. Food and Drug Administration (“FDA”) has granted orphan drug designation for autologous islet transplantation (“AIT”) for the prevention of diabetes due to total pancreatectomy.</p> <p align="justify">Sernova’s proprietary Cell Pouch Bio-hybrid Organ is designed to support the engraftment and long-term function of transplanted therapeutic cells. Chronic Pancreatitis causes debilitating http://www.streetinsider.com/Globe+Newswire/Sernova+Biotherapeutics+Receives+FDA+Orphan+Drug+Designation+for+Autologous+Islet+Transplantation+for+Prevention+of+Diabetes+Due+to+Total+Pancreatectomy/26656688.html Wed, 17 Jun 2026 07:00:00 -0400 A.06822034 A.28110669 O.03140503 O.20026344 O.48401414 PSH PSH.DE SEOVF SVA http://www.streetinsider.com/Globe+Newswire/Sernova+Biotherapeutics+Receives+FDA+Orphan+Drug+Designation+for+Autologous+Islet+Transplantation+for+Prevention+of+Diabetes+Due+to+Total+Pancreatectomy/26656688.html <p align="justify">TORONTO and BOSTON, June 17, 2026 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics Inc. (“Sernova” or the “Company”) (TSX: SVA) (OTC: SEOVF) (FSE/XETRA: PSHO), a leading regenerative medicine company focused on developing its Cell Pouch Bio-hybrid Organ as a functional cure for type 1 diabetes, today announced that the U.S. Food and Drug Administration (“FDA”) has granted orphan drug designation for autologous islet transplantation (“AIT”) for the prevention of diabetes due to total pancreatectomy.</p> <p align="justify">Sernova’s proprietary Cell Pouch Bio-hybrid Organ is designed to support the engraftment and long-term function of transplanted therapeutic cells. Chronic Pancreatitis causes debilitating http://www.streetinsider.com/Globe+Newswire/Sernova+Biotherapeutics+Receives+FDA+Orphan+Drug+Designation+for+Autologous+Islet+Transplantation+for+Prevention+of+Diabetes+Due+to+Total+Pancreatectomy/26656688.html Wed, 17 Jun 2026 07:00:00 -0400 A.06822034 A.28110669 O.03140503 O.20026344 O.48401414 PSH PSH.DE SEOVF SVA http://www.streetinsider.com/Globe+Newswire/Sernova+Biotherapeutics+Receives+FDA+Orphan+Drug+Designation+for+Autologous+Islet+Transplantation+for+Prevention+of+Diabetes+Due+to+Total+Pancreatectomy/26656688.html <p align="justify">TORONTO and BOSTON, June 17, 2026 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics Inc. (“Sernova” or the “Company”) (TSX: SVA) (OTC: SEOVF) (FSE/XETRA: PSHO), a leading regenerative medicine company focused on developing its Cell Pouch Bio-hybrid Organ as a functional cure for type 1 diabetes, today announced that the U.S. Food and Drug Administration (“FDA”) has granted orphan drug designation for autologous islet transplantation (“AIT”) for the prevention of diabetes due to total pancreatectomy.</p> <p align="justify">Sernova’s proprietary Cell Pouch Bio-hybrid Organ is designed to support the engraftment and long-term function of transplanted therapeutic cells. Chronic Pancreatitis causes debilitating http://www.streetinsider.com/Globe+Newswire/Sernova+Biotherapeutics+Receives+FDA+Orphan+Drug+Designation+for+Autologous+Islet+Transplantation+for+Prevention+of+Diabetes+Due+to+Total+Pancreatectomy/26656688.html Wed, 17 Jun 2026 07:00:00 -0400 A.06822034 A.28110669 O.03140503 O.20026344 O.48401414 PSH PSH.DE SEOVF SVA http://www.streetinsider.com/Globe+Newswire/Sernova+Biotherapeutics+Receives+FDA+Orphan+Drug+Designation+for+Autologous+Islet+Transplantation+for+Prevention+of+Diabetes+Due+to+Total+Pancreatectomy/26656688.html <p align="justify">TORONTO and BOSTON, June 17, 2026 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics Inc. (“Sernova” or the “Company”) (TSX: SVA) (OTC: SEOVF) (FSE/XETRA: PSHO), a leading regenerative medicine company focused on developing its Cell Pouch Bio-hybrid Organ as a functional cure for type 1 diabetes, today announced that the U.S. Food and Drug Administration (“FDA”) has granted orphan drug designation for autologous islet transplantation (“AIT”) for the prevention of diabetes due to total pancreatectomy.</p> <p align="justify">Sernova’s proprietary Cell Pouch Bio-hybrid Organ is designed to support the engraftment and long-term function of transplanted therapeutic cells. Chronic Pancreatitis causes debilitating http://www.streetinsider.com/Globe+Newswire/Sernova+Biotherapeutics+Receives+FDA+Orphan+Drug+Designation+for+Autologous+Islet+Transplantation+for+Prevention+of+Diabetes+Due+to+Total+Pancreatectomy/26656688.html Wed, 17 Jun 2026 07:00:00 -0400 A.06822034 A.28110669 O.03140503 O.20026344 O.48401414 PSH PSH.DE SEOVF SVA http://www.streetinsider.com/Globe+Newswire/Sernova+Biotherapeutics+Receives+FDA+Orphan+Drug+Designation+for+Autologous+Islet+Transplantation+for+Prevention+of+Diabetes+Due+to+Total+Pancreatectomy/26656688.html <p align="justify">TORONTO and BOSTON, June 17, 2026 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics Inc. (“Sernova” or the “Company”) (TSX: SVA) (OTC: SEOVF) (FSE/XETRA: PSHO), a leading regenerative medicine company focused on developing its Cell Pouch Bio-hybrid Organ as a functional cure for type 1 diabetes, today announced that the U.S. Food and Drug Administration (“FDA”) has granted orphan drug designation for autologous islet transplantation (“AIT”) for the prevention of diabetes due to total pancreatectomy.</p> <p align="justify">Sernova’s proprietary Cell Pouch Bio-hybrid Organ is designed to support the engraftment and long-term function of transplanted therapeutic cells. Chronic Pancreatitis causes debilitating http://www.streetinsider.com/Globe+Newswire/Sernova+Biotherapeutics+Receives+FDA+Orphan+Drug+Designation+for+Autologous+Islet+Transplantation+for+Prevention+of+Diabetes+Due+to+Total+Pancreatectomy/26656688.html Wed, 17 Jun 2026 07:00:00 -0400 A.06822034 A.28110669 O.03140503 O.20026344 O.48401414 PSH PSH.DE SEOVF SVA http://www.streetinsider.com/Globe+Newswire/Sernova+Biotherapeutics+Receives+FDA+Orphan+Drug+Designation+for+Autologous+Islet+Transplantation+for+Prevention+of+Diabetes+Due+to+Total+Pancreatectomy/26656688.html <p align="justify">TORONTO and BOSTON, June 17, 2026 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics Inc. (“Sernova” or the “Company”) (TSX: SVA) (OTC: SEOVF) (FSE/XETRA: PSHO), a leading regenerative medicine company focused on developing its Cell Pouch Bio-hybrid Organ as a functional cure for type 1 diabetes, today announced that the U.S. Food and Drug Administration (“FDA”) has granted orphan drug designation for autologous islet transplantation (“AIT”) for the prevention of diabetes due to total pancreatectomy.</p> <p align="justify">Sernova’s proprietary Cell Pouch Bio-hybrid Organ is designed to support the engraftment and long-term function of transplanted therapeutic cells. Chronic Pancreatitis causes debilitating http://www.streetinsider.com/Globe+Newswire/Sernova+Biotherapeutics+Receives+FDA+Orphan+Drug+Designation+for+Autologous+Islet+Transplantation+for+Prevention+of+Diabetes+Due+to+Total+Pancreatectomy/26656688.html Wed, 17 Jun 2026 07:00:00 -0400 A.06822034 A.28110669 O.03140503 O.20026344 O.48401414 PSH PSH.DE SEOVF SVA http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++SINOVAC+BIOTECH+LTD+++++++For%3A+Jun+15/26643855.html si-local-file:///var/storage/secattach/20260615/26643855.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++SINOVAC+BIOTECH+LTD+++++++For%3A+Jun+15/26643855.html Mon, 15 Jun 2026 06:21:00 -0400 O.09111766 SVA http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++SINOVAC+BIOTECH+LTD+++++++For%3A+Jun+15/26643855.html si-local-file:///var/storage/secattach/20260615/26643855.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++SINOVAC+BIOTECH+LTD+++++++For%3A+Jun+15/26643855.html Mon, 15 Jun 2026 06:21:00 -0400 O.09111766 SVA http://www.streetinsider.com/Corporate+News/SINOVAC+regains+Nasdaq+compliance+after+filing+annual+report/26643499.html <p>Sinovac Biotech Ltd. (NASDAQ: SVA) received notification that it has regained compliance with Nasdaq Global Market listing requirements, the Beijing-based biopharmaceutical company announced.</p><p>The company received a letter dated June 10, 2026, from a Nasdaq hearing advisor stating that Sinovac now complies with Listing Rule 5250(c)(1) and meets all listing requirements. The notification followed the company's filing of its annual report on Form 20-F for the year ended December 31, 2025, which was submitted on June 5, 2026.</p><p>A scheduled hearing before the Nasdaq Hearings Panel has been canceled as a result of the compliance restoration. However, Sinovac remains under a Mandatory http://www.streetinsider.com/Corporate+News/SINOVAC+regains+Nasdaq+compliance+after+filing+annual+report/26643499.html Mon, 15 Jun 2026 06:01:17 -0400 SVA http://www.streetinsider.com/Press+Releases/SINOVAC+Regained+Compliance+With+the+Nasdaq+Global+Market%E2%80%99s+Listing+Requirements/26643464.html <p> BEIJING--(BUSINESS WIRE)-- Sinovac Biotech Ltd. (Nasdaq: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated June 10, 2026 (the "Notification Letter"), from Hearing Advisor of The Nasdaq Stock Market LLC., indicating that the Company has regained compliance with Listing Rule 5250(c)(1) and that the Company is therefore in compliance with the Nasdaq Global Market's listing requirements. As noted in the Hearing Panel's May 20, 2026 compliance determination, the Company remains under a Mandatory Panel Monitor pursuant to Listing Rule 5815(d)(4)(B) until May 20, 2027. </p><p> The http://www.streetinsider.com/Press+Releases/SINOVAC+Regained+Compliance+With+the+Nasdaq+Global+Market%E2%80%99s+Listing+Requirements/26643464.html Mon, 15 Jun 2026 06:00:00 -0400 A.22491700 O.09111766 O.14923619 SVA http://www.streetinsider.com/Press+Releases/SINOVAC+Regained+Compliance+With+the+Nasdaq+Global+Market%E2%80%99s+Listing+Requirements/26643464.html <p> BEIJING--(BUSINESS WIRE)-- Sinovac Biotech Ltd. (Nasdaq: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated June 10, 2026 (the "Notification Letter"), from Hearing Advisor of The Nasdaq Stock Market LLC., indicating that the Company has regained compliance with Listing Rule 5250(c)(1) and that the Company is therefore in compliance with the Nasdaq Global Market's listing requirements. As noted in the Hearing Panel's May 20, 2026 compliance determination, the Company remains under a Mandatory Panel Monitor pursuant to Listing Rule 5815(d)(4)(B) until May 20, 2027. </p><p> The http://www.streetinsider.com/Press+Releases/SINOVAC+Regained+Compliance+With+the+Nasdaq+Global+Market%E2%80%99s+Listing+Requirements/26643464.html Mon, 15 Jun 2026 06:00:00 -0400 A.22491700 O.09111766 O.14923619 SVA http://www.streetinsider.com/Press+Releases/SINOVAC+Regained+Compliance+With+the+Nasdaq+Global+Market%E2%80%99s+Listing+Requirements/26643464.html <p> BEIJING--(BUSINESS WIRE)-- Sinovac Biotech Ltd. (Nasdaq: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated June 10, 2026 (the "Notification Letter"), from Hearing Advisor of The Nasdaq Stock Market LLC., indicating that the Company has regained compliance with Listing Rule 5250(c)(1) and that the Company is therefore in compliance with the Nasdaq Global Market's listing requirements. As noted in the Hearing Panel's May 20, 2026 compliance determination, the Company remains under a Mandatory Panel Monitor pursuant to Listing Rule 5815(d)(4)(B) until May 20, 2027. </p><p> The http://www.streetinsider.com/Press+Releases/SINOVAC+Regained+Compliance+With+the+Nasdaq+Global+Market%E2%80%99s+Listing+Requirements/26643464.html Mon, 15 Jun 2026 06:00:00 -0400 A.22491700 O.09111766 O.14923619 SVA http://www.streetinsider.com/Press+Releases/SINOVAC+Regained+Compliance+With+the+Nasdaq+Global+Market%E2%80%99s+Listing+Requirements/26643464.html <p> BEIJING--(BUSINESS WIRE)-- Sinovac Biotech Ltd. (Nasdaq: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated June 10, 2026 (the "Notification Letter"), from Hearing Advisor of The Nasdaq Stock Market LLC., indicating that the Company has regained compliance with Listing Rule 5250(c)(1) and that the Company is therefore in compliance with the Nasdaq Global Market's listing requirements. As noted in the Hearing Panel's May 20, 2026 compliance determination, the Company remains under a Mandatory Panel Monitor pursuant to Listing Rule 5815(d)(4)(B) until May 20, 2027. </p><p> The http://www.streetinsider.com/Press+Releases/SINOVAC+Regained+Compliance+With+the+Nasdaq+Global+Market%E2%80%99s+Listing+Requirements/26643464.html Mon, 15 Jun 2026 06:00:00 -0400 A.22491700 O.09111766 O.14923619 SVA